Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06440213
Other study ID # NRS/230703/PF/PDI
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 20, 2024
Est. completion date November 22, 2024

Study information

Verified date May 2024
Source Nuritas Ltd
Contact Niamh Mohan, PhD
Phone 014301290
Email mohan.niamh@nuritas.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomised, double blind, placebo controlled parallel study to examine the effects of a dose range of PeptiControl, a plant-based ingredient, in pre-diabetic males and females.


Description:

The primary aim of this study is to evaluate safety and establish the effective dose to see acute effects in males and females with elevated fasting blood glucose. PeptiControl will be supplemented 30 minutes before lunch as a single oral dose of either 2610mg, 870mg or 435mg/day. A placebo group will also be included who will receive microcrystalline cellulose. Capsule number will be matched across all study arms to retain double blinding. This trial incorporates continuous glucose monitoring (CGM) as wearable technology to measure blood glucose and time in range of the participants for the duration of the study. The trial will be conducted over 12 days, which includes a 2 day run-in period to gather baseline CGM data, followed by 6 days of PeptiControl supplementation and 4 days follow up on safety and blood glucose tracking post supplementation. The primary endpoint will measure safety and tolerability via adverse event reporting and occurrence of hypoglycemic episodes evaluated by time below target range (70 - 180 mg/dL) during CGM throughout the intervention. Secondary endpoints investigated during the trial will include safety of a dose range as assessed by a safety blood panel, glucose metabolism and insulin sensitivity, time in range, aspects of cognition and memory and hunger, satiety and fullness as assessed by VAS questionnaires.


Recruitment information / eligibility

Status Recruiting
Enrollment 124
Est. completion date November 22, 2024
Est. primary completion date November 22, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 30 Years to 60 Years
Eligibility Inclusion Criteria: - Males and Females (30-60 years of age) - Individuals with Body Mass Index (BMI) more than or equal to 25 and less than or equal to 33.0 kg/m² - Individuals with fasting blood glucose (FBG) more than or equal to 100 mg/dL and less than or equal to 125 mg/dL after 8-10 hours fasting. - Individual must be a non-smoker or an ex-smoker (5 years or more). - Have a stable body weight (less than or equal to 4.5 kgs change) in the last 3 months (as self-reported by the individual). - Be willing to maintain existing dietary habits and physical activity levels throughout the study period. - Individual must be willing to wear a continuous glucose monitor during the specific time in the study - Individual must be willing to attend all site visits and follow protocols for that visit, e.g., arrive fasting and provide blood samples. - Individuals who have given their signed Informed Consent. Exclusion Criteria: - Individuals having fasting blood glucose levels less than 100 mg/dL or more than 125 mg/dL. - Individuals having BMI outside the range of 25 - 33 kg/m². - Individuals who are presently dieting, or who were using medications affecting body weight or who had experienced a change in weight of more than 4.5 kg or a change in physical activity within the six months preceding the screening visit. - Individuals diagnosed with Type I Diabetes mellitus. - Individuals diagnosed with Type II Diabetes mellitus and currently on medication. - Individuals with Triglyceride levels more than 200 mg/dL, and/or liver function tests (AST, ALT) levels 1.5 times than the normal range, and/or kidney function test (serum creatinine) levels 1.5 times than the normal range. - Individuals with low haemoglobin or haematocrit (i.e., lower than normal ranges [less than 12.0 g/dL hemoglobin levels in women and less than 13.0 g/dL hemoglobin levels in men]) - Individuals having a significant acute or chronic co-existing illnesssuch as cardiovascular disease, chronic kidney or liver disease, gastrointestinal disorder, endocrine disorder, immunological disorder, metabolic disease, or any condition which contraindicates, in the investigator's judgement, entry to the study or which poses a significant risk to the individual. - Individuals diagnosed with hypertension (systolic blood pressure more than 140 mm Hg and/or diastolic blood pressure more than 90 mm Hg) and currently on medication. - Individuals who have unstable medical conditions or who are on chronic medication that has not been at a stable dose for at least 1 month. - Consumption of more than the recommended alcohol guidelines i.e., more than 21 alcohol units/week for males and more than 14 alcohol units/week for females. - Currently or recently (within 3 months of study entry) taking any medication, which in the opinion of the investigator, could interfere with the outcome of the study, including insulin, acetylsalicylic acid, thyroxine, beta blockers, or hypolipidemic agents. - Individuals on any medications associated with weight loss such as medication for the treatment of deficit hyperactivity, medication associated with weight gain like antipsychotics, or glucocorticoids, and/or immunosuppressants. - Have a known allergy or sensitivity to any compounds in the test material's active or inactive ingredients or placebo. - Individuals having a history of drug or alcohol abuse. - Individuals who have a history of neurological disorders or significant psychiatric illness, who are cognitively impaired and/or who are unable to give informed consent. - Present or recent use (within 3 months of pre-screening) of dietary supplements that may affect the level of blood glucose, e.g., chromium, dietary fibres, and non-digestible carbohydrates e.g., fructooligosaccharides chicory inulin, mulberry leaf extract. - Females who are pregnant, lactating or wish to become pregnant during the study. - Individuals with evidence of a clinically unstable disease (such as depression), as determined by medical history, physical examination, that, in the Investigator and medical monitors opinion, preclude entry into the study. - Breast feeding women. - Immune compromised individuals. - Individuals who have participated in a clinical study with an investigational product (IP) within 90 days before pre-screening, or who plan to participate in another study during the study period.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
PeptiControl™ (Low - Dose 435 mg/day)
Plant protein hydrolysate
PeptiControl™ (Mid - Dose 870 mg/day)
Plant protein hydrolysate
PeptiControl™ (High - Dose 2610 mg/day)
Plant protein hydrolysate
Placebo Microcrystalline Cellulose
Placebo MCC micro-crystalline cellulose

Locations

Country Name City State
India Chopda Medicare & Research Centre Nashik Maharashtra
India Vakretund Hospital Nashik Maharashtra
India Ashwin Medical Foundation Pune Maharashtra
India Imperial Multispeciality Hospital Pune Maharashtra

Sponsors (1)

Lead Sponsor Collaborator
Nuritas Ltd

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary To investigate the safety and tolerability of a range of doses of PeptiControl™ as assessed by occurrence of hypoglycemic episodes evaluated by time below target range (70 - 180 mg/dL) during Continuous Glucose Monitoring (CGM) The hypoglycemic events will be monitored and recorded from the day of IP initiation (Day 0) until the end of study (Day 10). The tolerability of different doses of PeptiControl™ will be assessed on the basis of the hypoglycemic episodes evaluated by time below target range (70 - 180 mg/dL) during CGM throughout the study in each arm. Day 0 to Day 10
Secondary To explore the safety of a range of doses of PeptiControl™ as assessed by a safety blood panel comparing baseline and post dose parameters. Blood samples will be taken from participants pre and post consumption of PeptiControl and analysed in a safety blood panel assessing liver, kidney and lipid markers for the identification of any changes from baseline. Day 0 and Day 6
Secondary To assess the efficacy of range of doses of PeptiControl™ on blood glucose concentrations when given 30 minutes prior to Oral Glucose Tolerance Test (OGTT) compared to placebo Thirty minutes post IP consumption, participants will consume a glucose solution (comprising of 75g glucose in approximately 250 ml water). Blood samples will then be collected at 15, 30, 60, 90, 120 and 180 mins for the assessment of blood glucose concentrations Day 0
Secondary To assess the efficacy of range of doses of PeptiControl™ on Glucose metabolism as assessed by incremental Area Under Curve (iAUC) The glucose iAUC will be derived from the OGTT. This assessment will be conducted at 0, 15, 30, 60, 90, 120 and 180 mins after glucose solution consumption Day 0
Secondary To assess the efficacy of range of doses of PeptiControl™ on Pancreatic efficiency Pancreatic efficiency will be evaluated by fasting serum insulin levels in blood Fasting insulin: Normal range - 2.6-24.9 µU/mL (17.8-173 pmol/L) Day 0 and Day 6
Secondary To assess the efficacy of range of doses of PeptiControl™ Time in range via CGM (Continuous Glucose Monitoring). Continuous glucose monitoring device automatically calculates the time in the blood glucose target range (70 - 180 mg/dl) as well as above and below the target range Starting from day -2 and worn continuously until day 10 with readings taken at day -2, day 0, day 6, day 10
Secondary To assess the efficacy of range of doses of PeptiControl™ on Insulin sensitivity as assessed by Homeostatic Model Assessment for Insulin Resistance (HOMA-IR). Insulin sensitivity will be assessed by HOMA-IR.
The HOMA - IR score will be calculated using the formula:
fasting insulin (mU/L) x fasting glucose (mmol/L)/22.5.
Fasting insulin: Normal range - 2.6-24.9 µU/mL (17.8-173 pmol/L) Fasting Glucose: Normal range - 4.11-6.05 mmol/L(74-109 mg/dL)
Day 0 and Day 6
Secondary To assess the efficacy of range of doses of PeptiControl™ on Working memory as assessed by Paired Associate Learning test Working memory will be assessed using the Validated Paired Associate Learning test by Creyos. Day 0, Day 6, and Day 10
Secondary To assess the efficacy of range of doses of PeptiControl™ on Selective attention as assessed by Stroop test. Selective attention will be assessed using the Double Trouble/Stroop test by Creyos Day 0, Day 6, and Day 10
Secondary To assess the efficacy of range of doses of PeptiControl™ on Hunger, satiety and fullness as assessed by the Visual Analog Scale (VAS) The VAS will be 100 mm in length with words anchored at each end expressing the most positive and the most negative rating. It will assess five components: hunger, satiety, fullness, prospective food consumption and desire to eat. Day 0, Day 6, and Day 10
See also
  Status Clinical Trial Phase
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Terminated NCT03299881 - Safety and Effectiveness of Transcutaneous Electrical Nerve Stimulation (TENS)-Assisted Weight Loss N/A
Completed NCT02805478 - Fat-Associated Cardiovascular Organ Dysfunction
Active, not recruiting NCT02558920 - Meta-analyses of Food Sources of Fructose-Containing Sugars and Obesity
Completed NCT03759743 - Evaluate the Efficacy and Safety of LMT1-48 on Reducing Body Fat in Overweight Subject N/A
Completed NCT03610958 - Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss. N/A
Completed NCT03678766 - CHARGE: Controlling Hunger and ReGulating Eating N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT05376865 - Effects of Vitamin D Supplementation on Obesity, Inflammatory and Metabolic Markers N/A
Completed NCT03625427 - Effect of Palmitoleic Acid on C-reactive Protein N/A
Active, not recruiting NCT03435445 - Online Platform for Healthy Weight Loss (POEmaS) N/A
Enrolling by invitation NCT05576116 - Combined Bariatric Surgery and Pancreas After Kidney Transplantation for Type II Diabetics N/A
Recruiting NCT05249465 - Spark: Finding the Optimal Tracking Strategy for Weight Loss in a Digital Health Intervention N/A
Active, not recruiting NCT06023095 - A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities Phase 1
Completed NCT03648892 - Brain Dopamine Function in Human Obesity Early Phase 1
Not yet recruiting NCT05751993 - Piloting a Reinforcement Learning Tool for Individually Tailoring Just-in-time Adaptive Interventions N/A
Recruiting NCT02887950 - Resistant Starch, Epigallocatechin Gallate and Chlorogenic Acid for Body Weight Loss in Menopause N/A
Completed NCT02899390 - Diabetes Prevention Program in Adults of the Yaqui Tribe of Hermosillo, Sonora at Risk of Diabetes N/A
Completed NCT03097237 - High Fiber Rye Foods for Weight and Body Fat Reduction N/A